Cargando…

Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine

The rapid growth of the global HIV/AIDS epidemic makes it a high priority to develop an effective vaccine. Since a live attenuated or inactivated HIV vaccine is not likely to be approved for clinical application due to safety concerns, HIV virus like particles (VLPs) offer an attractive alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, XiZhen, Wang, XiaoDan, Zhao, DongHai, Meng, XiangYu, Zhao, XingHong, Yu, XiangHui, Kong, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science China Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089044/
https://www.ncbi.nlm.nih.gov/pubmed/22173311
http://dx.doi.org/10.1007/s11427-011-4244-0
Descripción
Sumario:The rapid growth of the global HIV/AIDS epidemic makes it a high priority to develop an effective vaccine. Since a live attenuated or inactivated HIV vaccine is not likely to be approved for clinical application due to safety concerns, HIV virus like particles (VLPs) offer an attractive alternative because they are considered safer since they lack viral genome. We got a stable eukaryotic cell line by G418 resistance selection, engineered to express the HIV-1 structure protein Gag and Env efficiently and stably. We confirmed the presence of Gag and Env proteins in the cell culture supernatant and that they could self-assemble into VLPs. These VLPs were found to be able to elicit specific humoral and cellular immune response after immunization without any adjuvant.